HIV health care providers are ready to introduce pre-exposure prophylaxis in Central and Eastern Europe and neighbouring countries: data from the Euroguidelines in Central and Eastern Europe (ECEE) Network Group

the ECEE Network Group

doi:10.1111/hiv.12641

HIV health care providers are ready to introduce pre-exposure prophylaxis in Central and Eastern Europe and neighbouring countries: data from the Euroguidelines in Central and Eastern Europe (ECEE) Network Group

the ECEE Network Group

Department of Clinical Medicine

2 Citations (Scopus)

Abstract

Objectives: Pre-exposure prophylaxis (PrEP) for HIV infection has been introduced in only a few European countries. We investigated the potential to provide PrEP in the Central and Eastern European region, and in neighbouring countries. Methods: The Euroguidelines in Central and Eastern Europe (ECEE) Network Group was formed in February 2016 to review standards of care for HIV infection in the region. Information related to PrEP was collected through on-line surveys. Respondents were recruited by ECEE members based on their involvement in HIV care. Results: Seventy-six respondents from 23 countries participated in the survey. Twenty-six (34.2%) respondents reported that PrEP [tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)] was registered by the drug registration authority in their country. Fifty-three (70.7%) respondents reported being aware of ‘informal’ PrEP use in their country. If they had access to PrEP, 56 (74.7%) would advise its use in their practice. Forty-five (59.2%) respondents had concerns regarding PrEP use, and 10 (13.3%) expressed the need for more training. Most of the respondents (88.2%) would provide PrEP to people with high-risk behaviours. Conclusions: PrEP is already used informally in some countries in the region. Physicians are keen to use PrEP if and when it is accessible. Obstacles towards implementing PrEP in those countries were mostly related to lack of national guidelines, drug registration and governmental strategy.

Original language	English
Journal	HIV Medicine
Volume	19
Issue number	9
Pages (from-to)	629-633
Number of pages	5
ISSN	1464-2662
DOIs	https://doi.org/10.1111/hiv.12641
Publication status	Published - 2018

Keywords

central Europe
EACS
eastern Europe
Euroguidelines
HIV
pre-exposure prophylaxis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/hiv.12641

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/hiv.12641

Fingerprint

Dive into the research topics of 'HIV health care providers are ready to introduce pre-exposure prophylaxis in Central and Eastern Europe and neighbouring countries: data from the Euroguidelines in Central and Eastern Europe (ECEE) Network Group'. Together they form a unique fingerprint.

Cite this

HIV health care providers are ready to introduce pre-exposure prophylaxis in Central and Eastern Europe and neighbouring countries : data from the Euroguidelines in Central and Eastern Europe (ECEE) Network Group. / the ECEE Network Group.

In: HIV Medicine, Vol. 19, No. 9, 2018, p. 629-633.

Research output: Contribution to journal › Journal article › Research › peer-review

@article{7058e76aa89b439fb37923a013c66758,

title = "HIV health care providers are ready to introduce pre-exposure prophylaxis in Central and Eastern Europe and neighbouring countries: data from the Euroguidelines in Central and Eastern Europe (ECEE) Network Group",

abstract = "Objectives: Pre-exposure prophylaxis (PrEP) for HIV infection has been introduced in only a few European countries. We investigated the potential to provide PrEP in the Central and Eastern European region, and in neighbouring countries. Methods: The Euroguidelines in Central and Eastern Europe (ECEE) Network Group was formed in February 2016 to review standards of care for HIV infection in the region. Information related to PrEP was collected through on-line surveys. Respondents were recruited by ECEE members based on their involvement in HIV care. Results: Seventy-six respondents from 23 countries participated in the survey. Twenty-six (34.2%) respondents reported that PrEP [tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)] was registered by the drug registration authority in their country. Fifty-three (70.7%) respondents reported being aware of {\textquoteleft}informal{\textquoteright} PrEP use in their country. If they had access to PrEP, 56 (74.7%) would advise its use in their practice. Forty-five (59.2%) respondents had concerns regarding PrEP use, and 10 (13.3%) expressed the need for more training. Most of the respondents (88.2%) would provide PrEP to people with high-risk behaviours. Conclusions: PrEP is already used informally in some countries in the region. Physicians are keen to use PrEP if and when it is accessible. Obstacles towards implementing PrEP in those countries were mostly related to lack of national guidelines, drug registration and governmental strategy.",

keywords = "central Europe, EACS, eastern Europe, Euroguidelines, HIV, pre-exposure prophylaxis",

author = "Kowalska, {J. D.} and D. Bursa and D. G{\"o}kengin and D. Jilich and J. Tomazic and M. Vasylyev and P. Bukovinowa and V. Mulabdic and S. Antonyak and A. Horban and I. Alexiev and L. Afonina and T. Balayan and A. Bednarska and J. Begovac and E. Firl{\c a}g-Burkacka and N. Bolokadze and S. Caplinskas and G. Cholewi{\'n}ska-Szyma{\'n}ska and N. Chkhartishvili and {de Witt}, S. and G. Dragovic and A. Harxhi and J. Higersberger and T. Holban and D. Jevtovic and I. Karpov and D. Konopnicky and N. Ladnaya and B. Lakatos and Lundgren, {J. D.} and M. Mardarescu and B. Mat{\l}osz and Molina, {J. M.} and C. Oprea and D. Otelea and M. Paciorek and A. Panteleev and A. Papadopoulos and E. Pietraszkiewicz and B. Podlasin and D. Podlekareva and A. Pozniak and J. Pula and D. Sedlacek and A. Skrzat-Klapaczy{\'n}ska and J. Simonovi{\'c}-Babi{\'c} and M. Sluzhynska and A. Streinu-Cercel and N. Rukhadze and {the ECEE Network Group}",

year = "2018",

doi = "10.1111/hiv.12641",

language = "English",

volume = "19",

pages = "629--633",

journal = "HIV Medicine",

issn = "1464-2662",

publisher = "Wiley-Blackwell",

number = "9",

}

TY - JOUR

T1 - HIV health care providers are ready to introduce pre-exposure prophylaxis in Central and Eastern Europe and neighbouring countries

T2 - data from the Euroguidelines in Central and Eastern Europe (ECEE) Network Group

AU - Kowalska, J. D.

AU - Bursa, D.

AU - Gökengin, D.

AU - Jilich, D.

AU - Tomazic, J.

AU - Vasylyev, M.

AU - Bukovinowa, P.

AU - Mulabdic, V.

AU - Antonyak, S.

AU - Horban, A.

AU - Alexiev, I.

AU - Afonina, L.

AU - Balayan, T.

AU - Bednarska, A.

AU - Begovac, J.

AU - Firląg-Burkacka, E.

AU - Bolokadze, N.

AU - Caplinskas, S.

AU - Cholewińska-Szymańska, G.

AU - Chkhartishvili, N.

AU - de Witt, S.

AU - Dragovic, G.

AU - Harxhi, A.

AU - Higersberger, J.

AU - Holban, T.

AU - Jevtovic, D.

AU - Karpov, I.

AU - Konopnicky, D.

AU - Ladnaya, N.

AU - Lakatos, B.

AU - Lundgren, J. D.

AU - Mardarescu, M.

AU - Matłosz, B.

AU - Molina, J. M.

AU - Oprea, C.

AU - Otelea, D.

AU - Paciorek, M.

AU - Panteleev, A.

AU - Papadopoulos, A.

AU - Pietraszkiewicz, E.

AU - Podlasin, B.

AU - Podlekareva, D.

AU - Pozniak, A.

AU - Pula, J.

AU - Sedlacek, D.

AU - Skrzat-Klapaczyńska, A.

AU - Simonović-Babić, J.

AU - Sluzhynska, M.

AU - Streinu-Cercel, A.

AU - Rukhadze, N.

AU - the ECEE Network Group

PY - 2018

Y1 - 2018

N2 - Objectives: Pre-exposure prophylaxis (PrEP) for HIV infection has been introduced in only a few European countries. We investigated the potential to provide PrEP in the Central and Eastern European region, and in neighbouring countries. Methods: The Euroguidelines in Central and Eastern Europe (ECEE) Network Group was formed in February 2016 to review standards of care for HIV infection in the region. Information related to PrEP was collected through on-line surveys. Respondents were recruited by ECEE members based on their involvement in HIV care. Results: Seventy-six respondents from 23 countries participated in the survey. Twenty-six (34.2%) respondents reported that PrEP [tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)] was registered by the drug registration authority in their country. Fifty-three (70.7%) respondents reported being aware of ‘informal’ PrEP use in their country. If they had access to PrEP, 56 (74.7%) would advise its use in their practice. Forty-five (59.2%) respondents had concerns regarding PrEP use, and 10 (13.3%) expressed the need for more training. Most of the respondents (88.2%) would provide PrEP to people with high-risk behaviours. Conclusions: PrEP is already used informally in some countries in the region. Physicians are keen to use PrEP if and when it is accessible. Obstacles towards implementing PrEP in those countries were mostly related to lack of national guidelines, drug registration and governmental strategy.

AB - Objectives: Pre-exposure prophylaxis (PrEP) for HIV infection has been introduced in only a few European countries. We investigated the potential to provide PrEP in the Central and Eastern European region, and in neighbouring countries. Methods: The Euroguidelines in Central and Eastern Europe (ECEE) Network Group was formed in February 2016 to review standards of care for HIV infection in the region. Information related to PrEP was collected through on-line surveys. Respondents were recruited by ECEE members based on their involvement in HIV care. Results: Seventy-six respondents from 23 countries participated in the survey. Twenty-six (34.2%) respondents reported that PrEP [tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)] was registered by the drug registration authority in their country. Fifty-three (70.7%) respondents reported being aware of ‘informal’ PrEP use in their country. If they had access to PrEP, 56 (74.7%) would advise its use in their practice. Forty-five (59.2%) respondents had concerns regarding PrEP use, and 10 (13.3%) expressed the need for more training. Most of the respondents (88.2%) would provide PrEP to people with high-risk behaviours. Conclusions: PrEP is already used informally in some countries in the region. Physicians are keen to use PrEP if and when it is accessible. Obstacles towards implementing PrEP in those countries were mostly related to lack of national guidelines, drug registration and governmental strategy.

KW - central Europe

KW - EACS

KW - eastern Europe

KW - Euroguidelines

KW - HIV

KW - pre-exposure prophylaxis

U2 - 10.1111/hiv.12641

DO - 10.1111/hiv.12641

M3 - Journal article

C2 - 29989332

AN - SCOPUS:85050500214

SN - 1464-2662

VL - 19

SP - 629

EP - 633

JO - HIV Medicine

JF - HIV Medicine

IS - 9

ER -